WO2011047146A3 - Procédés de maturation d'affinité d'anticorps - Google Patents

Procédés de maturation d'affinité d'anticorps Download PDF

Info

Publication number
WO2011047146A3
WO2011047146A3 PCT/US2010/052660 US2010052660W WO2011047146A3 WO 2011047146 A3 WO2011047146 A3 WO 2011047146A3 US 2010052660 W US2010052660 W US 2010052660W WO 2011047146 A3 WO2011047146 A3 WO 2011047146A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
affinity maturing
antibodies
maturing antibodies
affinity
Prior art date
Application number
PCT/US2010/052660
Other languages
English (en)
Other versions
WO2011047146A2 (fr
Inventor
Juan-Carlos Almagro
Johan Fransson
Gopalan Raghunathan
Original Assignee
Centocor Ortho Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc. filed Critical Centocor Ortho Biotech Inc.
Priority to JP2012534354A priority Critical patent/JP2013508287A/ja
Priority to ES10824085T priority patent/ES2826883T3/es
Priority to DK10824085.4T priority patent/DK2488867T3/da
Priority to EP10824085.4A priority patent/EP2488867B1/fr
Publication of WO2011047146A2 publication Critical patent/WO2011047146A2/fr
Publication of WO2011047146A3 publication Critical patent/WO2011047146A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur des procédés de maturation d'affinité d'anticorps.
PCT/US2010/052660 2009-10-14 2010-10-14 Procédés de maturation d'affinité d'anticorps WO2011047146A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012534354A JP2013508287A (ja) 2009-10-14 2010-10-14 抗体を親和性成熟する方法
ES10824085T ES2826883T3 (es) 2009-10-14 2010-10-14 Métodos de maduración por afinidad de anticuerpos
DK10824085.4T DK2488867T3 (da) 2009-10-14 2010-10-14 Fremgangsmåder til affinitetsmodning af antistoffer
EP10824085.4A EP2488867B1 (fr) 2009-10-14 2010-10-14 Procédés de maturation d'affinité d'anticorps

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25144509P 2009-10-14 2009-10-14
US61/251,445 2009-10-14

Publications (2)

Publication Number Publication Date
WO2011047146A2 WO2011047146A2 (fr) 2011-04-21
WO2011047146A3 true WO2011047146A3 (fr) 2011-06-16

Family

ID=43876863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/052660 WO2011047146A2 (fr) 2009-10-14 2010-10-14 Procédés de maturation d'affinité d'anticorps

Country Status (6)

Country Link
US (1) US8580714B2 (fr)
EP (1) EP2488867B1 (fr)
JP (1) JP2013508287A (fr)
DK (1) DK2488867T3 (fr)
ES (1) ES2826883T3 (fr)
WO (1) WO2011047146A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
CN103261223B (zh) * 2010-10-13 2017-03-29 詹森生物科技公司 人制瘤素m抗体及使用方法
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
WO2013054320A1 (fr) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam)
CA3234629A1 (fr) 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anticorps anti-phf-tau et leurs utilisations
WO2013172961A1 (fr) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions et méthodes destinées à diagnostiquer et à traiter des tumeurs
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
AU2013358944B2 (en) * 2012-12-13 2016-08-18 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
SG10201802295XA (en) * 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
SG10201913627TA (en) 2014-04-08 2020-03-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
EP3766902A1 (fr) 2014-04-27 2021-01-20 FameWave Ltd. Anticorps humanisés dirigés contre ceacam1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
JP6574257B2 (ja) 2014-10-07 2019-09-11 アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ 新規の抗Ｎｏｄａｌ抗体及びその使用方法
CA2975851A1 (fr) * 2015-02-06 2016-08-11 National University Of Singapore Procedes pour ameliorer l'efficacite de cellules immunitaires therapeutiques
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
CA3014934A1 (fr) 2016-03-04 2017-09-08 JN Biosciences, LLC Anticorps anti-tigit
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
KR20240099512A (ko) 2016-11-22 2024-06-28 싱가포르국립대학교 T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CN111247241A (zh) 2017-08-10 2020-06-05 新加坡国立大学 T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
WO2019099454A2 (fr) 2017-11-15 2019-05-23 Philippe Valadon Bibliothèques d'anticorps hautement fonctionnelles
US11377487B2 (en) * 2018-01-15 2022-07-05 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
MA52235A (fr) 2018-03-05 2021-02-17 Janssen Pharmaceutica Nv Anticorps anti-phf-tau et leurs utilisations
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN113272322A (zh) * 2018-10-08 2021-08-17 Uab 研究基金会 神经内分泌癌靶向治疗
AU2020313981A1 (en) 2019-07-17 2022-03-03 Gemini Therapeutics Sub, Inc. Factor H potentiating antibodies and uses thereof
WO2021127621A2 (fr) * 2019-12-19 2021-06-24 Overa, Inc. Compositions et procédés de contraception spécifique aux ovocytes
US11820824B2 (en) 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2022003693A1 (fr) * 2020-07-02 2022-01-06 Biolojic Design Ltd. Anticorps anti-récepteur du facteur de nécrose tumorale (tnfr2) et leurs utilisations
CN113512109B (zh) * 2021-03-09 2022-03-25 北京康乐卫士生物技术股份有限公司 一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117659201B (zh) * 2022-08-23 2024-09-24 东莞市朋志生物科技有限公司 抗可卡因抗体或其功能性片段、检测可卡因的试剂和试剂盒
CN116731184B (zh) * 2022-11-25 2024-06-14 厦门康基生物科技有限公司 一种特异性结合Taq酶的单克隆抗体F6H12及其应用
CN116003619B (zh) * 2022-12-12 2023-08-04 三门峡市眼科医院 人源化抗Ang-2和VEGF双功能抗体及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK0494955T3 (da) * 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2340857T3 (es) 1997-09-16 2010-06-10 Centocor Ortho Biotech Inc. Metodo para la sintesis quimica completa y emsamblaje de genes y genomas.
US6670127B2 (en) * 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
CN1672160B (zh) * 2002-05-20 2010-06-09 埃博马可西斯公司 基于前导抗体的结构构建抗体文库的方法
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2006014498A2 (fr) 2004-07-06 2006-02-09 Bioren, Inc. Bibliotheques d'anticorps universelles
JP2009515516A (ja) * 2005-11-14 2009-04-16 バイオレン・インク 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
AU2008343589A1 (en) * 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
WO2010021874A2 (fr) * 2008-08-20 2010-02-25 Centocor Ortho Biotech Inc. Anticorps anti-il-13 modifiés, compositions, procédés et utilisations
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COBAUGH ET AL.: "Synthetic antibody libraries focused towards peptide ligands", J MOL BIOL., vol. 378, no. 3, 2008, pages 622 - 633, XP022762539 *
LAUNE D. ET AL.: "Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 49, 1997, pages 30937 - 30944, XP002563413 *
PADLAN E.A. ET AL.: "Identification of specificity-determining residues in antibodies", FASEB J., vol. 9, 1995, pages 133 - 139, XP003010923 *
STEIDL ET AL.: "In vitro affinity maturation of human GM-CSF antibodies by targeted CDR diversification", MOLECULAR IMMUNOLOGY, vol. 46, 2008, pages 135 - 144, XP025472134 *

Also Published As

Publication number Publication date
WO2011047146A2 (fr) 2011-04-21
EP2488867A2 (fr) 2012-08-22
US8580714B2 (en) 2013-11-12
DK2488867T3 (da) 2020-11-09
EP2488867B1 (fr) 2020-09-30
JP2013508287A (ja) 2013-03-07
US20110092372A1 (en) 2011-04-21
ES2826883T3 (es) 2021-05-19
EP2488867A4 (fr) 2014-05-07

Similar Documents

Publication Publication Date Title
WO2011047146A3 (fr) Procédés de maturation d'affinité d'anticorps
WO2012061607A3 (fr) Compositions comprenant des nanostructures fonctionnalisées à base de carbone et procédés associés
WO2011056644A3 (fr) Anticorps anti-glp-1r et leurs utilisations
HK1219741A1 (zh) 結構域抗體的生產方法
WO2012131555A3 (fr) Immunoglobulines hétéro-dimériques
WO2013096380A3 (fr) Anticorps anti-phf-tau et leurs utilisations
WO2013046060A9 (fr) Papier et procédés de fabrication du papier
WO2012107778A3 (fr) Pores mutants
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
WO2011133504A3 (fr) Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes
WO2011075636A3 (fr) Épitopes et agents de liaison destinés à wise
WO2011142970A3 (fr) Aptamères d'acide nucléique her2
EP3514173B8 (fr) Anticorps contre dkk-1
EP3214066B8 (fr) Procédé de préparation de fluoroalkyl fluoroformiates
WO2012099930A3 (fr) Compositions de flavonol
WO2011017330A8 (fr) Formulations de polypeptide concentrées à viscosité réduite
WO2012149334A3 (fr) Procédés et compositions pour préparer et utiliser des anticorps spécifiques à une conformation
WO2012064743A3 (fr) Procédés d'amélioration de la fonction cardiaque
WO2008075205A3 (fr) Procédé amélioré de préparation de la voriconazole
WO2010015656A3 (fr) Nouveaux alcoxypyrazoles
WO2013016280A3 (fr) Compositions et procédés pour sélectionner des aptamères
WO2011050188A8 (fr) Anticorps anti-hepsine et procédés d'utilisation de ceux-ci
MX339772B (es) Metodo y composicion para producir azucar clarificada.
WO2011017031A3 (fr) Dispositifs endovasculaires favorisant la guérison
WO2012095432A3 (fr) Agents de liaison à tlr3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10824085

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012534354

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010824085

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10824085

Country of ref document: EP

Kind code of ref document: A2